2025
Risk of Atherosclerotic Cardiovascular Disease After Chronic Obstructive Pulmonary Disease Hospitalization among Primary and Secondary Prevention Older Adults
Mosher C, Osazuwa‐Peters O, Nanna M, MacIntyre N, Que L, Palmer S, Jones W, O'Brien E. Risk of Atherosclerotic Cardiovascular Disease After Chronic Obstructive Pulmonary Disease Hospitalization among Primary and Secondary Prevention Older Adults. Journal Of The American Heart Association 2025, 14: e035010. PMID: 39791395, PMCID: PMC12054414, DOI: 10.1161/jaha.124.035010.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary disease hospitalizationsChronic obstructive pulmonary diseaseAtherosclerotic cardiovascular diseaseSecondary prevention cohortPrevention cohortASCVD hospitalizationRisk of atherosclerotic cardiovascular diseaseHazard ratioHospital outcomesHigh riskRisk factorsCardiovascular disease eventsCardiovascular diseasePrimary prevention cohortIdentified multiple risk factorsRisk of cardiovascular disease eventsMultiple risk factorsPulmonary disease hospitalizationsObstructive pulmonary diseaseOlder adultsHigh-risk patient cohortASCVD eventsDisease eventsHigh-risk patientsMeta-analyses
2022
Abstract 14830: Comparative Cost-Effectiveness of Cardioprotective Glucose-Lowering Therapies for Type 2 Diabetes in a Middle-Income Country: A Bayesian Network Model
Carvalho L, Nogueira A, Antunes J, Moura F, Luchiari B, Bonilha I, Nadruz W, Gaziano M, Gaziano T, Sposito A. Abstract 14830: Comparative Cost-Effectiveness of Cardioprotective Glucose-Lowering Therapies for Type 2 Diabetes in a Middle-Income Country: A Bayesian Network Model. Circulation 2022, 146: a14830-a14830. DOI: 10.1161/circ.146.suppl_1.14830.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioGLP-1RAMiddle-income countriesType 2 diabetesCardiovascular eventsRisk of non-fatal cardiovascular eventsFollow-up >Pre-specified endpointsCohort of T2D patientsNon-fatal cardiovascular eventsGlucose-lowering therapySecondary prevention cohortAdverse cardiovascular eventsAnti-diabetic therapyRandomized clinical trialsCost-effectiveness ratioBrazilian public health systemDouble-blindGLP1-RAPublic health systemPrevention cohortProspective cohortT2D subjectsHeart failureT2D patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply